Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients.

Najjar-Debbiny, Ronza; Gronich, Naomi; Weber, Gabriel; Khoury, Johad; Amar, Maisam; Stein, Nili; Goldstein, Lee Hilary; Saliba, Walid

Najjar-Debbiny, Ronza; Gronich, Naomi; Weber, Gabriel; Khoury, Johad; Amar, Maisam; Stein, Nili; Goldstein, Lee Hilary; Saliba, Walid.

Afiliación

Najjar-Debbiny R; Infection Control and Prevention Unit, Lady Davis Carmel Medical Center, Haifa, Israel.
Gronich N; Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Weber G; Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Khoury J; Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Haifa, Israel.
Amar M; Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Stein N; Infectious Diseases Unit, Lady Davis Carmel Medical Center, Haifa, Israel.
Goldstein LH; Pulmonology Division, Lady Davis Carmel Medical Center, Haifa, Israel.
Saliba W; Pulmonology, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

Clin Infect Dis ; 76(3): e342-e349, 2023 02 08.

Article en En | MEDLINE | ID: mdl-35653428

Asunto(s)

COVID-19; Enfermedades Cardiovasculares; Adulto; Humanos; Anciano; Vacunas contra la COVID-19; SARS-CoV-2

Palabras clave

COVID-19; Paxlovid; SARS-CoV-2; nirmatrelvir/ritonavir; vaccine

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / COVID-19 Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Israel

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google